Inimmune Corporation and Intrommune Therapeutics announce a collaboration to advance a revolutionary rapid, long-acting oral mucosal allergy immunotherapy for the treatment of peanut allergy
08 janv. 2024 09h05 HE
|
Intrommune Therapeutics
Inimmune Corporation and Intrommune Therapeutics announce a collaboration to advance a revolutionary rapid, long-acting oral mucosal allergy immunotherapy
US Food Allergen Testing Market Outlook to 2028 - New York Commands Attention in the Eastern Region with Innovative Allergens Detection Technology
14 déc. 2023 11h08 HE
|
Research and Markets
Dublin, Dec. 14, 2023 (GLOBE NEWSWIRE) -- The "US Food Allergen Testing Market Outlook to 2028" report has been added to ResearchAndMarkets.com's offering. With the increasing prevalence of food...
Intrommune Therapeutics Presents Positive Results of Phase 1 OMEGA Study Investigating the Safety of INT301 Toothpaste for the Treatment of Peanut Allergy
09 nov. 2023 11h01 HE
|
Intrommune Therapeutics
Intrommune Therapeutics Presents Positive Results of Phase 1 OMEGA Study Investigating the Safety of INT301 Toothpaste for the Treatment Peanut Allergy
Pet Allergy Treatment Industry Analysis: Anticipated Market to Reach a Size of US$ 4.1 Billion by 2033, Persistence Market Research
24 août 2023 08h54 HE
|
Persistence Market Research
New York, Aug. 24, 2023 (GLOBE NEWSWIRE) -- The global pet allergy treatment market reached a size of US$ 2.1 billion in 2022 and is forecasted to expand at a CAGR of 6.3% from 2023 to 2033,...
The Difference Baker Partners With George Mason University and Sodexo to Create the First True Allergy-Friendly Dining Experience on a U.S. College Campus
09 août 2023 15h46 HE
|
The Difference Baker
ASHBURN, Va., Aug. 09, 2023 (GLOBE NEWSWIRE) -- The Difference Baker is thrilled to announce a historic collaboration with George Mason University (GMU) and Sodexo, establishing the first retail...
Intrommune Therapeutics Completes Last Patient Last Visit in the Phase 1 OMEGA Study for Peanut Allergy
25 juil. 2023 09h35 HE
|
Intrommune Therapeutics
NEW YORK, July 25, 2023 (GLOBE NEWSWIRE) -- Intrommune Therapeutics, Inc., a clinical stage biotechnology company developing a patient-friendly treatment platform for peanut and other food...
Sublingual Allergy Immunotherapy Market Size to Surpass US$ 1.02 billion by 2033 at a CAGR of 9.1%| Persistence Market Research
12 juin 2023 09h45 HE
|
Persistence Market Research
New York, June 12, 2023 (GLOBE NEWSWIRE) -- The sublingual allergy immunotherapy (SLIT) market has been experiencing steady growth in recent years due to increasing prevalence of allergies and...
Insights on the Allergy Immunotherapies Global Market to 2028: Rising Awareness of Allergy Immunotherapies, Elevating Income Levels and Increasing Healthcare Expenditure Drives Growth
21 févr. 2023 13h18 HE
|
Research and Markets
Dublin, Feb. 21, 2023 (GLOBE NEWSWIRE) -- The "Allergy Immunotherapies Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028" report has been added to ...
Intrommune Therapeutics Completes Enrollment in the Phase 1 OMEGA Study for Peanut Allergy
26 oct. 2022 09h35 HE
|
Intrommune Therapeutics
Observed only mild and transient adverse events, with no use of emergency epinephrine Observed 98.4% patient compliance to date with novel OMIT therapeutic modality Safely started patients on dose...
Intrommune Expands and Strengthens Senior Leadership Team
28 sept. 2022 09h35 HE
|
Intrommune Therapeutics
Appointment of Stuart Loesch as President Leverages His Strong Leadership Abilities and Extensive Expertise in Allergy and Pharmaceutical Development Appointment of William Berger, MD, MBA as Head of...